Effective Dec. 8, 2020, Wisconsin Diagnostic Laboratories (WDL) is implementing a new Urinalysis System. With this implementation, reference ranges and reportable results will change for select tests included in routine urinalysis testing.

Effective Nov. 23, 2020, Hepatitis B Surface Antibody test will now display a quantitative, as well as qualitative result,

Reminder: The Urine Fentanyl screening test is offered by WDL.

Effective Nov. 19, 2020, Wisconsin Diagnostic Laboratories (WDL) will begin offering sex hormone binding globulin as well as free and bioavailable testosterone testing in-house.

Effective Nov. 19, 2020, Wisconsin Diagnostic Laboratories (WDL) is updating total testosterone reference intervals.

Effective Nov. 10, 2020, Wisconsin Diagnostic Laboratories (WDL) will be updating the reportable range for Low Molecular Weight Heparin (LMWH).

Effective Oct. 8, 2020, Wisconsin Diagnostic Laboratories (WDL) will begin offering anti-mullerian hormone (AMH) testing in-house.

Effective Sept. 1, 2020, Wisconsin Diagnostic Laboratories is Discontinuing the Platelet Mapping Test.

Effective Aug. 17, 2020, Chromogranin A testing will be performed using an alternate method. Since Chromogranin A tests are not harmonized, quantitative results are not directly comparable between the current and new test.

Effective July 8, 2020, Wisconsin Diagnostic Laboratories will begin offering a new test for fecal calprotectin.

SARS-CoV-2 IgG Antibody Testing is now available at Wisconsin Diagnostic Laboratories (WDL).

Effective June 17, 2020, Wisconsin Diagnostic Laboratories will be offering a new urine drug screening test for Fentanyl.

Effective June 16, 2020, Wisconsin Diagnostic Laboratories is moving QuantiFERON-TB Gold Plus testing to a new instrument system.

Effective May 20, 2020, Wisconsin Diagnostic Laboratories (WDL) has updated the names for Routine Culture and Aerobic/Anaerobic Culture.

Effective May 20, 2020, Wisconsin Diagnostic Laboratories (WDL) is updating urine drug screening.

Effective April 10, 2020, the reference range and the Heparin Therapeutic Range for Activated Partial Thromboplastin Time (PTT) will change.

Effective March 24, 2020, Wisconsin Diagnostic Laboratories will replace aging instruments in the Chemistry laboratory with new instruments.

Effective Feb. 2020, Wisconsin Diagnostic Laboratories will begin offering an immunohistochemistry PD-L1 stain and a Mismatch Repair Panel. Bringing this testing in-house considerably improves turnaround time.

Clarification regarding Fetal Cell Detection (Kleihauer Stain) Reporting Change

Effective Jan. 29, 2020, WDL is updating syphilis testing.

Effective Jan. 29, 2020, WDL will begin in-house testing for the anti-epileptic drug CLOBAZAM (ONFI) and its active metabolite DESMETHYLCLOBAZAM. Bringing this test in-house will significantly improve turnaround time.

Effective Jan. 15, 2020, WDL will offer a new test for assessment of vitamin B12 status, VITAMIN B12 REFLEX TO METHYLMALONIC ACID. This new reflex test will be the preferred test for assessment of vitamin B12 status, replacing parallel testing of vitamin B12 and methylmalonic acid. This change aligns with current best-practices, which recommend methylmalonic acid testing only as follow up in cases of borderline deficient or low vitamin B12.